Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD107 in venous thromboembolism prevention after knee arthroplasty
NCT07140523Phase 2Recruiting
- Sponsor
- Sirius Therapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of SRSD107 in venous thromboembolism (VTE) (4 arms), sponsored by Sirius Therapeutics. Primary endpoint: Incidence of total venous thromboembolism events. Started Sep 2025; status: recruiting.
02
Drugs
SRSD107
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07140523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140523.